Determination of Pancreatic Steatosis Prevalence and Correlation With High-risk Cyst Features

Launched by CHINESE UNIVERSITY OF HONG KONG · Apr 13, 2022

Keywords

ClinConnect Summary

This clinical trial is investigating how common a condition called pancreatic steatosis (which is the buildup of fat in the pancreas) is and how it relates to certain high-risk features of pancreatic cysts. The goal is to better understand these conditions because pancreatic cancer is very serious and hard to detect early. The study aims to improve how we can prevent and treat pancreatic cancer, especially for people who are at higher risk, such as those with a family history of the disease.

To be eligible for this trial, participants need to be 18 years or older and have at least one pancreatic cyst that is a certain size, or they can be healthy individuals without any cysts. Participants will need to be able to provide consent and follow the study procedures. If you join the study, you’ll undergo imaging tests to help researchers gather information about your pancreas and any cysts present. It's important to note that individuals with known pancreatic cancer or certain other health issues may not be able to participate. This study is currently recruiting participants, and your involvement could contribute to vital research that helps improve pancreatic cancer outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18 or older
• • 2. Patients with at least 1 pancreatic cystic lesion presumed to be IPMN or MCN based on CT, MRI or EUS features, with a cyst size ≥ 5mm; or healthy subjects.
• • 3. Patients who are able to provide written informed consent to participate in the study and comply with the study procedures.
• Exclusion Criteria:
• • 1. Unable to provide written informed consent
• • 2. Patients with metallic implants or other contraindications to MRI
• • 3. Patients with contraindications for endoscopy due to comorbidities
• • 4. Patients with known pancreatic cancer or prior pancreatic resection
• • 5. Patients with significant alcohol consumption, defined as alcohol intake of over 20 g daily (140 g weekly) for men and 10 g daily (70 g weekly) for women